SERPINB10

Serpin B10 · P48595 · SERPINB10 on Sugi Atlas →

0 patent compounds predicted against SERPINB10, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to SERPINB10 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency PHASE4RECRUITING
Atorvastatin in Acute Stroke Treatment PHASE4COMPLETED
Metformin Use in Cardiac Fibrosis in PAI-1 Deficiency PHASE4ACTIVE_NOT_RECRUITING
Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography PHASE4UNKNOWN
Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma PHASE4NOT_YET_RECRUITING
International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema PHASE2/PHASE3COMPLETED
Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency PHASE2/PHASE3COMPLETED
Donidalorsen Treatment in Children With Hereditary Angioedema PHASE3RECRUITING
Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases PHASE2/PHASE3COMPLETED
Single Dose Administration of Alpha-1 Anti-Trypsin for the Amelioration of Organ Injury in Patients Undergoing Cardiac Surgery PHASE1/PHASE2UNKNOWN
The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B) PHASE1/PHASE2COMPLETED
JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure PHASE1/PHASE2NOT_YET_RECRUITING
Study of the Safety and Efficacy of Intravenous Alpha-1 Antitrypsin in Type 1 Diabetes Mellitus PHASE1/PHASE2COMPLETED
Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients PHASE2UNKNOWN
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC PHASE2RECRUITING
A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer PHASE2UNKNOWN
A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors PHASE1/PHASE2RECRUITING
Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age PHASE2RECRUITING
A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer PHASE2NOT_YET_RECRUITING
Identification and Characterization of Genetic Variants in Hereditary Angioedema nanNOT_YET_RECRUITING
Belgian Antithrombin Deficiency Registry nanNOT_YET_RECRUITING
Genetic Mechanisms of Chronic Obstructive Pulmonary Disease (COPD) nanCOMPLETED
SerpinB3 Expression, PAR2 and SCCA-PD Polymorphism in Acute Respiratory Distress Syndrome nanRECRUITING
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis nanRECRUITING
Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals nanCOMPLETED
Study of Individuals Affected With Hypoplasminogenemia nanRECRUITING
Alpha-1 Carrier Genomics Study nanCOMPLETED
Genomic Research in Alpha-1 Antitrypsin Deficiency nanCOMPLETED
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study nanRECRUITING
Peri-implantitis and MMP-8 nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SERPINB10 binder may also engage these)

ProteinNameSimilarity
A9RA96 1.000 A9RA96 →
B2KI30 1.000 B2KI30 →
B3RFC3 1.000 B3RFC3 →
B0CMB0 0.999 B0CMB0 →
Q96P15 0.997 Q96P15 →
B1MTC3 0.997 B1MTC3 →
Q9UIV8 0.995 Q9UIV8 →
B4USX2 0.994 B4USX2 →
O73790 0.994 O73790 →
A5PJK0 0.993 A5PJK0 →
Q8K1K6 0.993 Q8K1K6 →
P01014 0.992 P01014 →
O73860 0.991 O73860 →
P12388 0.991 P12388 →
Q96P63 0.988 Q96P63 →
Q8K3K4 0.987 Q8K3K4 →
P29508 0.986 P29508 →
P29524 0.986 P29524 →
Q8CDC0 0.985 Q8CDC0 →
P48594 0.985 P48594 →
E2RVI8 0.984 E2RVI8 →
P05120 0.982 P05120 →
Q9D695 0.982 Q9D695 →
O75635 0.982 O75635 →
Q9D7P9 0.981 Q9D7P9 →
Q52L45 0.981 Q52L45 →
P01012 0.980 P01012 →
Q9CQV3 0.980 Q9CQV3 →
P19104 0.978 P19104 →
Q6V115 0.978 Q6V115 →